• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Spark Therapeutics Appoints CTO

    Cryoport Launches ESG Program

    U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail

    Thermo Fisher Scientific Completes Mesa Biotech Acquisition

    Ashfield Engage, Popit Form Digital Monitoring Collaboration
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Solid Dose Market Trends

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    C2 Pharma Completes Multiple Regulatory Filings

    Bormioli Opens New Glass Research Center
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing

    PwC Joins Medicines Manufacturing Innovation Centre
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Ashfield Engage, Popit Form Digital Monitoring Collaboration

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    CrownBio & JSR Life Sciences Partner with Cambridge Quantum Computing
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Alcami

    Aphena Pharma Solutions

    test company saurabh

    Adare Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    test company saurabh

    Aphena Pharma Solutions

    Emergent BioSolutions

    Baxter BioPharma Solutions

    Reed-Lane
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Top Companies Report

    12 Amgen

    ...

    12 Amgen
    Amgen strengthened its pipeline in 2019 with the $13.4 billion deal for Celgene's Otezla.
    Related CONTENT
    • Syntegon Validates First AI-equipped Visual Inspection System
    • EVOQ Therapeutics and Amgen Partner
    • Amgen Ends Cardio Alliance with Cytokinetics
    • Financial Report: Amgen
    • Lilly Submits EUA Request for COVID-19 Monotherapy
    Tim Wright, Editor, Contract Pharma07.20.20
    Headquarters: Thousand Oaks, CA
    twitter.com/Amgen
    www.amgen.com

    Headcount:  22,000
    Year Established: 1980
    Revenues:  $23,362 (-2%)
    Net Income:  $7,842  (-7%)
    R&D:  $4,116 (+10%)

    TOP SELLING DRUGS
    Drug Indication 2019 Sales (+/-%)
    Enbrel rheumatoid arthritis $5,226 4%
    Neulasta  chemotherapy induced neutropenia $3,221 -28%
    Prolia bone cancer $2,672 17%
    Xgeva  bone cancer $1,935 8%
    Aranesp  chemotherapy induced anemia  $1,729 -8%
    Kyprolis multiple myeloma $1,044 %
    Epogen anemia $867 -14%
    Nplate immune thromboytopenia $795 11%
    Vectibix colorectal cancer $744 8%
    Repatha hypercholesterolaemia $661 20%
     

    In 2019, Amgen’s newer drugs continued to drive growth, though not enough to offset revenues falling 2% to $23.4 billion. To bolster its portfolio, Amgen executed a major deal during the year to expand its inflammation franchise when it agreed to pay $13.4 billion for Celgene’s Otezla (apremilast), the only oral, non-biologic treatment for psoriasis and psoriatic arthritis. Amgen said that the acquisition is a strong strategic fit with its inflammation franchise offering a differentiated, oral therapy, along with Otezla’s sales growth potential over the next five years. Sales of Otezla in 2018 were $1.6 billion. 

    Otezla is currently approved for three indications in the U.S., including patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy; adult patients with active psoriatic arthritis; and adult patients with oral ulcers associated with Behçet's Disease. Otezla is approved in more than 50 markets outside the U.S., including the EU and Japan, and has patent exclusivity through at least 2028 in the U.S.

    More positive news was reported in 2019 when Amgen launched Evenity, the first and only osteoporosis treatment that both increases bone formation and reduces bone loss, thereby rapidly reducing the risk of fracture.
     
    China expansion plans unfold
    Amgen made its intentions clear to expand in China when it entered into a strategic collaboration with BeiGene that will significantly accelerate its expansion plans in the country. BeiGene is a research-based, oncology-focused biotechnology company with an established and experienced team in China, including a 700-person commercial organization and a 600-person clinical development organization. As part of the collaboration Amgen paid $2.7 billion for a 20.5% stake in BeiGene.

    Under the agreement, BeiGene will commercialize Xgeva, Kyprolis and Blincyto in China during which time the parties will equally share profits and losses. Two of these products will revert to Amgen, one after five years and one after seven years. Following the commercialization period, BeiGene will have the right to retain one product and will be entitled to receive royalties on sales in China for an additional five years on the products not retained. Xgeva was launched in China in September of 2019; Kyprolis and Blincyto are both in Phase 3 trials in China.

    The two companies will collaborate to advance 20 medicines from Amgen's innovative oncology pipeline in China and globally. BeiGene will share global research and development costs and contribute up to $1.25 billion to advance these medicines. Amgen will pay royalties to BeiGene on sales of these products outside of China, with the exception of AMG 510, Amgen's first-in-class KRASG12C inhibitor that is being studied as a potential treatment for solid tumors.

    Of the 20 oncology medicines, BeiGene will assume commercial rights in China for seven years after launch for those that receive approval in China, including AMG 510. After this time, BeiGene will retain rights to up to six of these products in China, excluding AMG 510, while rights on remaining products revert to Amgen.

    Amgen will continue to commercialize its non-oncology product portfolio in China. Earlier this year, Amgen launched its first-ever product in China, Repatha, an LDL cholesterol-lowering treatment proven to reduce the risk of heart attacks and stroke. Amgen expects to launch a number of other non-oncology medicines in China over the next several years, including Prolia, which reduces the risk of fracture in postmenopausal women with osteoporosis.

    Xgeva, Kyprolis and Blincyto, as well as the medicines in Amgen's oncology pipeline, will be manufactured at Amgen's existing facilities.
     
    Drug discovery and research
    To boost its drug discovery platform, in 2019 Amgen acquired Copenhagen, Denmark-based Nuevolution, for $167 million. Now called Amgen Research Copenhagen, the company has developed Chemetics,  a pioneering technology in the emerging field of DNA-encoded libraries. In a DNA-encoded library, each compound is tagged with a unique sequence of DNA that functions like a barcode, and mixtures containing billions of unique DNA-tagged compounds can be screened in a single small test tube, according to the company.

    In a research collaboration, Amgen and Syapse, a precision medicine insight company, entered a partnership to develop observational research analytics to assess treatment outcomes for areas of unmet need in oncology.
    This effort aims to identify existing patients within the Syapse Learning Health Network that could be eligible for Amgen-sponsored clinical trials and to bring these trials to community health system sites. The companies will create opportunities for physicians and researchers within the Syapse Network to gain access to analytics, real-world evidence-based insights, and collaborative research opportunities.

    Amgen will have access to real-world evidence for potential use in regulatory filings in support of certain agreed upon development candidates in oncology. Amgen will also work with Syapse to develop real-world evidence standards to support the acceleration of therapies to market.  

    In another research tie-up, Amgen and the University of Washington's Institute for Protein Design (IPD) entered a broad collaboration that will cover multiple projects with a goal of testing new technologies and creating protein-building approaches that can be broadly applied to drug research.

    This will include optimizing Amgen's repertoire of BiTE (bispecific T cell engager) antibodies, with the goal of expanding the types of tumors that can be targeted with these molecules. IPD's expertise could also help Amgen to generate antibodies against very challenging drug targets and to devise new ways to modulate the activity of the immune system. In the longer-term, the broad-based collaboration could help shape the discovery and development of protein-based therapies.

    To further enhance its R&D capabilities, at the end of the year, Amgen signed a lease with BioMed Realty for a new 240,000-square-foot Leadership in Energy and Environmental Design (LEED) candidate facility in the Gateway of Pacific campus development in South San Francisco. The new location, currently under construction at Oyster Point, will house Amgen's Bay Area employees focused on cardiometabolic, inflammation and oncology, research. The new site will include modular green wet labs and green molecular lab design and is scheduled to open in early 2022.
    Suggested For You
    Syntegon Validates First AI-equipped Visual Inspection System Syntegon Validates First AI-equipped Visual Inspection System
    EVOQ Therapeutics and Amgen Partner EVOQ Therapeutics and Amgen Partner
    Amgen Ends Cardio Alliance with Cytokinetics Amgen Ends Cardio Alliance with Cytokinetics
    Financial Report: Amgen Financial Report: Amgen
    Lilly Submits EUA Request for COVID-19 Monotherapy Lilly Submits EUA Request for COVID-19 Monotherapy
    Lilly, Amgen Enter Antibody Mfg. Pact for COVID-19 Therapies Lilly, Amgen Enter Antibody Mfg. Pact for COVID-19 Therapies
    SomaLogic, Amgen Enter Proteomic Profiling Pact SomaLogic, Amgen Enter Proteomic Profiling Pact
    Amgen’s Expansion Plans in China Underway Amgen’s Expansion Plans in China Underway
    Amgen Completes Otezla Acquisition  Amgen Completes Otezla Acquisition

    Related Top Companies Report

    • 25 CSL Behring

      25 CSL Behring

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.20.20

    • 22 Astellas

      22 Astellas

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.20.20

    • 21 Biogen

      21 Biogen

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.20.20


    • 13 Gilead Sciences

      13 Gilead Sciences

      ...
      Kristin Brooks, Managing Editor 07.15.20

    • 10 Bristol-Myers Squibb

      10 Bristol-Myers Squibb

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.15.20

    • 03 Novartis

      03 Novartis

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20


    • 02 Roche

      02 Roche

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 09 Takeda

      09 Takeda

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 01 Pfizer, Inc.

      01 Pfizer, Inc.

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20


    • The 2020 Top 25 Pharma and Biopharma Companies

      The 2020 Top 25 Pharma and Biopharma Companies

      Top 25 Pharma and Biopharma Companies (Based on 2019 Pharma/Biopharma Sales, in $U.S. Millions)
      Contract Pharma Staff 07.15.20

    • 08 GlaxoSmithKline

      08 GlaxoSmithKline

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 07 AbbVie

      07 AbbVie

      ...
      Kristin Brooks , Managing Editor, Contract Pharma 07.15.20


    • 06 Sanofi

      06 Sanofi

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 05 Merck

      05 Merck

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 04 Johnson & Johnson

      04 Johnson & Johnson

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    Trending
    • Catalent Acquires Delphi Genetics
    • Inside A Vaccine Trial
    • Pfizer Selects Seven Bridges To Support RNA Sequencing Data
    • Pfizer Partners With Medicines Manufacturing Innovation Center
    • ICON Acquires Medpass
    Breaking News
    • Spark Therapeutics Appoints CTO
    • Cryoport Launches ESG Program
    • U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail
    • Thermo Fisher Scientific Completes Mesa Biotech Acquisition
    • Ashfield Engage, Popit Form Digital Monitoring Collaboration
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Preliminary Study Links Markers of Impaired Bone Health to Vegan Diet
    Refined Grains Linked to Heart Attack Risk, Early Death
    Kappa Bioscience Extends Research Partnership For COVID-19 Research
    Coatings World

    Latest Breaking News From Coatings World

    Nippon Paint Marine Wins Korea Export Award
    Universal Display Corporation, PPG Expand Global Production of UniversalPHOLED Materials
    PPG Introduces Premium Iso-free Primer Surfacer, Catalyst
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    January AI Raises $8.8 Million in New Funding
    FDA Clears Ava Fertility Tracking Wearable Device
    First Patient in Europe Treated With Diamondback 360 Coronary Orbital Atherectomy System
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Spark Therapeutics Appoints CTO
    Cryoport Launches ESG Program
    U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    The Top Beauty Products of 2021, According to HelloGiggles
    Estée Lauder Taps Ana de Armas as Global Brand Ambassador
    Sephora Announces Significant Expansion
    Happi

    Latest Breaking News From Happi

    ACI Urges Senate to Approve Regan as EPA Administrator
    Estée Lauder Signs Actress Ana de Armas
    GUM Recalls Oral Spray
    Ink World

    Latest Breaking News From Ink World

    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Marshall & Bruce Adds Koenig & Bauer Rapida 106 41-Inch Seven-Color Press
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    FTA converts Forum & INFOFLEX to virtual events
    Xeikon launches two new digital label printing presses
    UFlex adds capacity in packaging films
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Texas Medical Technology Partners with My Protect Kit
    Mexico City Single-Use Plastics Ban Leads to Tampon Shortage
    Believe Diapers Launch in U.S.
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Fusion Robotics Receives FDA Clearance for Spinal Navigation and Robotics System
    Kaia Health Unveils Next-Gen Complete MSK Care Solutions
    First Implantation of CTL Amedica's Minimally Invasive Flex Tower
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login